Application of DNA methylation biomarkers for endometrial cancer management

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet355, 1404–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa B, Badzio A, Jassem J. Surgery followed by radiotherapy in endometrial cancer. Analysis of survival and patterns of failure. Int. J. Gynecol. Cancer9, 285–294 (1999).
   PubMed Web of Science ®Google Scholar
• Bocker T, Ruschoff J, Fishel R. Molecular diagnostics of cancer predisposition. Hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim. Biophys. Acta1423, O1–O10 (1999).
   Google Scholar
• Esteller M. Epigenetic lesions causing genetic lesions in human cancer. Promoter hypermethylation of DNA repair genes. Eur. J. Cancer36, 2294–2300 (2000).
   PubMed Web of Science ®Google Scholar
• Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA95, 6870–6875 (1998).
   PubMed Web of Science ®Google Scholar
• Furlan D, Carnevali I, Marcomini B et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin. Cancer Res.12, 3329–3336 (2006).
   PubMed Web of Science ®Google Scholar
• Macdonald ND, Salvesen HB, Ryan A et al. Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. Int. J. Gynecol. Cancer14, 957–965 (2004).
   PubMed Web of Science ®Google Scholar
• Salvesen HB, MacDonald N, Ryan A et al.PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer91, 22–26 (2001).
   PubMed Web of Science ®Google Scholar
• Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am. J. Obstet. Gynecol.158, 796–807 (1988).
   PubMed Web of Science ®Google Scholar
• Sasaki M, Dharia A, Oh BR et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res.61, 97–102 (2001).
   PubMed Web of Science ®Google Scholar
• Xiong Y, Dowdy SC, Gonzalez Bosquet J et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol. Oncol.99, 135–141 (2005).
   PubMed Web of Science ®Google Scholar
• Whitcomb BP, Mutch DG, Herzog TJ et al. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin. Cancer Res.9, 2277–2287 (2003).
   PubMed Web of Science ®Google Scholar
• Dowdy SC, Gostout BS, Shridhar V et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol. Oncol.99, 126–134 (2005).
   PubMed Web of Science ®Google Scholar
• Chan QK, Khoo US, Chan KY et al. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J. Mol. Diagn.7, 8–16 (2005).
   PubMed Web of Science ®Google Scholar
• Grady WM, Willis J, Guilford PJ et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet.26, 16–17 (2000).
   PubMed Web of Science ®Google Scholar
• Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst.92, 564–569 (2000).
   PubMed Web of Science ®Google Scholar
• Jolly CJ, Neuberger MS. Somatic hypermutation of immunoglobulin kappa transgenes. Association of mutability with demethylation. Immunol. Cell Biol.79, 18–22 (2001).
   PubMed Web of Science ®Google Scholar
• Florl AR, Franke KH, Niederacher D et al. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab. Invest.80, 1513–1522 (2000).
   PubMed Web of Science ®Google Scholar
• Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol.32, 569–577 (2001).
   PubMed Web of Science ®Google Scholar
• Dodge JE, Okano M, Dick F et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem.280, 17986–17991 (2005).
   PubMed Web of Science ®Google Scholar
• Pradhan M, Abeler VM, Danielsen HE et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod. Pathol.19, 1227–1235 (2006).
   Web of Science ®Google Scholar
• Umbricht CB, Evron E, Gabrielson E et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene20, 3348–3353 (2001).
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Battagli C, Esteller M et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res.64, 6476–6481 (2004).
   PubMed Web of Science ®Google Scholar
• Esteller M, Catasus L, Matias-Guiu X et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol.155, 1767–1772 (1999).
   PubMed Web of Science ®Google Scholar
• Norris HJ, Connor MP, Kurman RJ. Preinvasive lesions of the endometrium. Clin. Obstet. Gynaecol.13, 725–738 (1986).
   Google Scholar
• Fox H, Buckley CH. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology6, 493–510 (1982).
   PubMed Web of Science ®Google Scholar
• Nasir A, Boulware D, Kaiser HE et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo21, 35–43 (2007).
   Google Scholar
• Horowitz N, Pinto K, Mutch DG et al. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol. Oncol.86, 62–68 (2002).
   PubMed Web of Science ®Google Scholar
• Wang C, Mirkin BL, Dwivedi RS. DNA (cytosine) methyltransferase overexpression is associated with acquired drug resistance of murine neuroblastoma cells. Int. J. Oncol.18, 323–329 (2001).
   Google Scholar
• Saito T, Nishimura M, Yamasaki H, Kudo R. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer97, 1002–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Nakayama H, Sano T, Motegi A et al. Increasing 14-3-3 sigma expression with declining estrogen receptor a and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol. Int.55, 707–715 (2005).
   Google Scholar
• Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors. From bench to bedside. Cancer Lett.251, 187–198 (2007).
   PubMed Web of Science ®Google Scholar
• Shi H, Wang MX, Caldwell CW. CpG islands. Their potential as biomarkers for cancer. Expert Rev. Mol. Diagn.7, 519–531 (2007).
   PubMed Web of Science ®Google Scholar
• Baylin SB. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol.2, S4–S11 (2005).
   PubMedGoogle Scholar
• Laird PW. Cancer epigenetics. Hum. Mol. Genet.14, R65–R76 (2005).
   PubMed Web of Science ®Google Scholar
• Issa JP. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res.13, 1634–1637 (2007).
   PubMed Web of Science ®Google Scholar
• Fiegl H, Elmasry K. Cancer diagnosis, risk assessment and prediction of therapeutic response by means of DNA methylation markers. Dis. Markers23, 89–96 (2007).
   Google Scholar
• Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer. Potential prognostic and therapeutic targets. Methods Mol. Biol.361, 25–62 (2007).
   PubMedGoogle Scholar
• Liu ZJ, Maekawa M. Polymerase chain reaction-based methods of DNA methylation analysis. Anal. Biochem.317, 259–265 (2003).
   PubMedGoogle Scholar
• Yang HJ, Liu VW, Wang Y et al. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer6, 212 (2006).
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Goodfellow PJ, Schmidt AP et al. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clin. Cancer Res.13, 2882–2889 (2007).
   Google Scholar
• Paz MF, Wei S, Cigudosa JC et al. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum. Mol. Genet.12, 2209–2219 (2003).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Kim MS, Ostrow KL et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res.68, 2661–2670 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Itoh F, Toyota M et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int. J. Cancer83, 309–313 (1999).
   PubMed Web of Science ®Google Scholar
• Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA). Methods Mol. Biol.200, 71–85 (2002).
   PubMedGoogle Scholar
• Uhlmann K, Brinckmann A, Toliat MR et al. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis23, 4072–4079 (2002).
   PubMed Web of Science ®Google Scholar
• Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques35, 146–150 (2003).
   PubMed Web of Science ®Google Scholar
• Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation. Potential applications for disease diagnosis, classification, and prognosis in clinical settings. J. Mol. Med.84, 365–377 (2006).
   PubMedGoogle Scholar
• Bearzatto A, Conte D, Frattini M et al. p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin. Cancer Res.8, 3782–3787 (2002).
   PubMed Web of Science ®Google Scholar
• Ulivi P, Zoli W, Calistri D et al. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J. Cell Physiol.206, 611–615 (2006).
   PubMed Web of Science ®Google Scholar
• Xie GS, Hou AR, Li LY et al. Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin. Med. J.119, 1469–1472 (2006).
   Google Scholar
• Chuang CK, Chu DC, Tzou RD et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev.31, 59–63 (2007).
   PubMedGoogle Scholar
• Herman JG. Circulating methylated DNA. Ann. NY Acad. Sci.1022, 33–39 (2004).
   PubMedGoogle Scholar
• Schmiemann V, Bocking A, Kazimirek M et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates. A cohort study. Clin. Cancer Res.11, 7728–7734 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang P, Watanabe H, Okada G et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci.97, 1267–1273 (2006).
   Google Scholar
• Watanabe H, Okada G, Ohtsubo K et al. Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms. Pancreas32, 382–389 (2006).
   Google Scholar
• Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst.98, 996–1004 (2006).
   PubMedGoogle Scholar
• Belinsky SA, Palmisano WA, Gilliland FD et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res.6, 2370–2377 (2002).
   Google Scholar
• Smith RA, von Eschenbach AC, Wender R et al. American Cancer Society guidelines for the early detection of cancer. Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also Update 2001 – testing for early lung cancer detection. CA Cancer J. Clin.51, 38–75; quiz 77–80 (2001).
   PubMed Web of Science ®Google Scholar
• Bader GM, Simon TR, Koss LG, Day E. A study of the detection-tampon method as a screening device for uterine cancer. Cancer10, 332–337 (1957).
   Google Scholar
• Brunschwig A. Detection of endometrial adenocarcinoma by tampon-smear method. Cancer10, 120–123 (1957).
   Google Scholar
• Brunschwig A. A method for mass screening for cytological detection of carcinoma of the cervix uteri. Cancer7, 1182–1184 (1954).
   Google Scholar
• Papanicolaou GN. Cytological evaluation of smears prepared by the tampon method for the detection of carcinoma of the uterine cervix. Cancer7, 1185–1190 (1954).
   Web of Science ®Google Scholar
• Barrett KF, Bledsoe S, Greer BE et al. Tampon-induced vaginal or cervical ulceration. Am. J. Obstet. Gynecol.127, 332–333 (1977).
   PubMed Web of Science ®Google Scholar
• Weissberg SM, Dodson MG. Recurrent vaginal and cervical ulcers associated with tampon use. JAMA250, 1430–1431 (1983).
   Google Scholar
• Kehrberg MW, Latham RH, Haslam BT et al. Risk factors for staphylococcal toxic-shock syndrome. Am. J. Epidemiol.114, 873–879 (1981).
   Google Scholar
• Fox H. The pathology of tampon usage and of the toxic shock syndrome. Postgrad. Med. J.61(Suppl. 1), 31–33 (1985).
   Google Scholar
• Widschwendter A, Gattringer C, Ivarsson L et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin. Cancer Res.10, 3396–3400 (2004).
   PubMedGoogle Scholar
• Fiegl H, Gattringer C, Widschwendter A et al. Methylated DNA collected by tampons – a new tool to detect endometrial cancer. Cancer Epidemiol. Biomarkers Prev.13, 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Campan M, Weisenberger DJ, Laird PW. DNA methylation profiles of female steroid hormone-driven human malignancies. Curr. Top. Microbiol. Immunol.310, 141–178 (2006).
   PubMedGoogle Scholar
• Kang S, Kim JW, Kang GH et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer. Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Cancer118, 2168–2171 (2006).
   PubMed Web of Science ®Google Scholar
• Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin. Cancer Biol.9, 349–357 (1999).
   PubMed Web of Science ®Google Scholar
• Issa JP. CpG island methylator phenotype in cancer. Nat. Rev. Cancer4, 988–993 (2004).
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Kirkner GJ et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Possible associations with male sex and KRAS mutations. J. Mol. Diagn.8, 582–588 (2006).
   PubMedGoogle Scholar
• Ogino S, Kawasaki T, Kirkner GJ et al. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer7, 72 (2007).
   PubMedGoogle Scholar
• Goel A, Nagasaka T, Arnold CN et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology132, 127–138 (2007).
   PubMedGoogle Scholar
• Curtin K, Slattery ML, Ulrich CM et al. Genetic polymorphisms in one-carbon metabolism. associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis28, 1672–1679 (2007).
   PubMed Web of Science ®Google Scholar
• Slattery ML, Curtin K, Sweeney C et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int. J. Cancer120, 656–563 (2007).
   PubMed Web of Science ®Google Scholar
• Shen L, Catalano PJ, Benson AB III et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res.13, 6093–6098 (2007).
   PubMed Web of Science ®Google Scholar
• Ogino S, Meyerhardt JA, Kawasaki T et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch.450, 529–537 (2007).
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Hall GL, Lowe D et al. CpG island methylation phenotype (CIMP) in oral cancer. associated with a marked inflammatory response and less aggressive tumour biology. Oral. Oncol.43, 878–886 (2007).
   Google Scholar
• Mell LK, Meyer JJ, Tretiakova M et al. Prognostic significance of E-cadherin protein expression in pathological stage I–III endometrial cancer. Clin. Cancer Res.10, 5546–5553 (2004).
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Stefansson I, Kretzschmar EI et al. Significance of PTEN alterations in endometrial carcinoma. A population-based study of mutations, promoter methylation and PTEN protein expression. Int. J. Oncol.25, 1615–1623 (2004).
   PubMedGoogle Scholar
• Dowdy SC, Jiang S, Zhou XC et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther.5, 2767–2776 (2006).
   PubMed Web of Science ®Google Scholar
• Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res.10, 1141–1149 (2004).
   PubMed Web of Science ®Google Scholar
• Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol.108, 27–33 (2008).
   Google Scholar
• Jiang S, Dowdy SC, Meng XW et al. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol. Oncol.105, 493–500 (2007).
   Google Scholar
• Podratz KC. Hormonal therapy in endometrial carcinoma. Recent Results Cancer Res.118, 242–251 (1990).
   Google Scholar
• Lentz SS. Endocrine therapy of endometrial cancer. Cancer Treat. Res.94, 89–106 (1998).
   PubMedGoogle Scholar
• Dai D, Wolf DM, Litman ES et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness. down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res.62, 881–886 (2002).
   PubMed Web of Science ®Google Scholar
• Dai D, Albitar L, Nguyen T et al. A therapeutic model for advanced endometrial cancer. Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol. Cancer Ther.4, 169–175 (2005).
   Google Scholar
• Lentz SS, Brady MF, Major FJ et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. J. Clin. Oncol.14, 357–361 (1996).
   PubMed Web of Science ®Google Scholar
• Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet.36, 497–501 (2004).
   PubMed Web of Science ®Google Scholar
• Hitchins MP, Wong JJ, Suthers G et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med.356, 697–705 (2007).
   PubMed Web of Science ®Google Scholar
• Martin DI, Ward R, Suter CM. Germline epimutation. A basis for epigenetic disease in humans. Ann. NY Acad. Sci.1054, 68–77 (2005).
   PubMed Web of Science ®Google Scholar
• Valle L, Carbonell P, Fernandez V et al. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer. Clin. Genet.71, 232–237 (2007).
   Google Scholar
• Chan TL, Yuen ST, Kong CK et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet.38, 1178–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Horsthemke B. Epimutations in human disease. Curr. Top. Microbiol. Immunol.310, 45–59 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson B. Impact of aging on DNA methylation. Ageing Res. Rev.2, 245–261 (2003).
   PubMed Web of Science ®Google Scholar
• Rath PC, Kanungo MS. Methylation of repetitive DNA sequences in the brain during aging of the rat. FEBS Lett.244, 193–198 (1989).
   Google Scholar
• Romanov GA, Vanyushin BF. Methylation of reiterated sequences in mammalian DNAs. Effects of the tissue type, age, malignancy and hormonal induction. Biochim. Biophys. Acta653, 204–218 (1981).
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl Acad. Sci. USA94, 2545–2550 (1997).
   PubMed Web of Science ®Google Scholar
• Issa JP, Vertino PM, Boehm CD et al. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc. Natl Acad. Sci. USA93, 11757–11762 (1996).
   PubMed Web of Science ®Google Scholar
• Ahuja N, Li Q, Mohan AL et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res.58, 5489–5494 (1998).
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96, 8681–8686 (1999).
   PubMed Web of Science ®Google Scholar